The European Partnership for Personalized Medicine (EP PerMed) was born with the ambition of becoming a global platform dedicated to precision medicine whose objective is to encourage dialogue and the exchange of information on the activities and progress of the sector through research, development, innovation and implementation of personalized medicine approaches for the benefit of patients, citizens and society. With a total budget of approximately 335 million euros and the involvement of over 50 European and non-European partners, EP PerMed aims to support the implementation of personalized medicine approaches over the next ten years, but also their effective translation into clinical practice. A project involving 24 countries including two non-EU states such as Canada and Israel, and over 20 European states: Italy, Germany, France, Spain, Norway, Ireland, Austria, Lithuania, Estonia, Turkey, Sweden, Poland, Portugal, countries Netherlands, Luxembourg, Belgium, Finland, Sweden, Denmark, Hungary, Latvia, Iceland, Romania who, for the first time together, work on the introduction and development of Personalized Medicine within all European healthcare systems. Among the Italian partners, the Fondazione Toscana Life Sciences has assumed the role of leader of the innovation and internationalization pillars.
The EP PerMed project involves the investment of 335 million euros aimed at supporting research and development activities dedicated to the applications of personalized medicine through the promotion of annual joint transnational calls, events and activities to support innovation and the implementation of tools such as therapies, diagnostic devices and new approaches for screening.